Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lewy bodies and dementia.

D Galasko1

  • 1Department of Neurology, Veterans Affairs Medical Center, 127, 3350 La Jolla Village Drive, San Diego, CA 92161, USA. dgalasko@ucsd.edu

Current Neurology and Neuroscience Reports
|March 20, 2002
PubMed
Summary

Dementia with Lewy bodies (DLB) is characterized by widespread Lewy bodies (LBs) in the brain. Research is refining diagnostic criteria and exploring treatments like cholinesterase inhibitors for cognitive symptoms.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU): Trial Satisfaction and Attitudes towards Future Clinical Trials.

The journal of prevention of Alzheimer's disease..·2024
Same author

Dependence Levels as Interim Clinical Milestones Along the Continuum of Alzheimer's Disease: 18-Month Results from the GERAS Observational Study.

The journal of prevention of Alzheimer's disease·2017
Same author

Clinical and Economic Characteristics of Milestones along the Continuum of Alzheimer's Disease: Transforming Functional Scores into Levels of Dependence.

The journal of prevention of Alzheimer's disease·2017
Same author

Walking stabilizes cognitive functioning in Alzheimer's disease (AD) across one year.

Archives of gerontology and geriatrics·2012
Same author

A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease.

Neurology·2011
Same author

Global clinical dementia rating of 0.5 in MCI masks variability related to level of function.

Neurology·2011

Area of Science:

  • Neuropathology
  • Clinical Neurology
  • Neuroscience

Background:

  • The presence of Lewy bodies (LBs) in dementia patients has led to the identification of dementia with Lewy bodies (DLB).
  • Existing diagnostic criteria for DLB, established in 1995, are undergoing rigorous evaluation for clinical applicability.
  • Advancements in neuropathologic studies are facilitated by alpha-synuclein probes, crucial for LB identification.

Purpose of the Study:

  • To scrutinize the diagnostic criteria for dementia with Lewy bodies (DLB).
  • To investigate the role of widespread Lewy bodies (LBs) in the limbic or cortical areas contributing to dementia.
  • To explore pharmacologic management strategies for cognitive and behavioral symptoms in DLB patients.

Main Methods:

  • Review and analysis of existing diagnostic criteria for DLB.
  • Neuropathologic examination utilizing probes targeting alpha-synuclein.
  • Evaluation of therapeutic interventions for DLB symptoms.

Main Results:

  • The 1995 DLB diagnostic criteria demonstrate high specificity but variable sensitivity.
  • Widespread Lewy bodies (LBs) in limbic or cortical regions are associated with dementia.
  • Cholinesterase inhibitors show potential benefits for managing cognitive and behavioral symptoms in DLB.

Conclusions:

  • Further refinement of DLB diagnostic criteria is necessary for improved clinical application.
  • Alpha-synuclein targeted probes are vital tools for neuropathologic diagnosis of DLB.
  • Cholinesterase inhibitors represent a promising therapeutic avenue for dementia with Lewy bodies.

Related Experiment Videos